|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chavan S, Bray F, Lortet-Tieulent J,
Goodman M and Jemal A: International variations in bladder cancer
incidence and mortality. Eur Urol. 66:59–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gudjónsson S, Adell L, Merdasa F, Olsson
R, Larsson B, Davidsson T, Richthoff J, Hagberg G, Grabe M, Bendahl
PO, et al: Should all patients with non-muscle-invasive bladder
cancer receive early intravesical chemotherapy after transurethral
resection? The results of a prospective randomised multicentre
study. Eur Urol. 55:773–780. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Metts MC, Metts JC, Milito SJ and Thomas
CR Jr: Bladder cancer: A review of diagnosis and management. J Natl
Med Assoc. 92:285–294. 2000.PubMed/NCBI
|
|
5
|
Kaufman DS, Shipley WU and Feldman AS:
Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brausi M, Witjes JA, Lamm D, Persad R,
Palou J, Colombel M, Buckley R, Soloway M, Akaza H and Böhle A: A
review of current guidelines and best practice recommendations for
the management of nonmuscle invasive bladder cancer by the
International Bladder Cancer Group. J Urol. 186:2158–2167. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brausi M, Oddens J, Sylvester R, Bono A,
van de Beek C, van Andel G, Gontero P, Turkeri L, Marreaud S,
Collette S, et al: Side effects of Bacillus Calmette-Guérin (BCG)
in the treatment of intermediate- and high-risk Ta, T1 papillary
carcinoma of the bladder: Results of the EORTC genito-urinary
cancers group randomised phase 3 study comparing one-third dose
with full dose and 1 year with 3 years of maintenance BCG. Eur
Urol. 65:69–76. 2014. View Article : Google Scholar
|
|
8
|
Smith TJ: Mechanisms of carcinogenesis
inhibition by isothiocyanates. Expert Opin Investig Drugs.
10:2167–2174. 2001. View Article : Google Scholar
|
|
9
|
Xiao D, Bommareddy A, Kim SH, Sehrawat A,
Hahm ER and Singh SV: Benzyl isothiocyanate causes FoxO1-mediated
autophagic death in human breast cancer cells. PLoS One.
7:e325972012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin JF, Tsai TF, Liao PC, Lin YH, Lin YC,
Chen HE, Chou KY and Hwang TI: Benzyl isothiocyanate induces
protective autophagy in human prostate cancer cells via inhibition
of mTOR signaling. Carcinogenesis. 34:406–414. 2013. View Article : Google Scholar
|
|
11
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iorio MV and Croce CM: Causes and
consequences of microRNA dysregulation. Cancer J. 18:215–222. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Phuah NH and Nagoor NH: Regulation of
microRNAs by natural agents: New strategies in cancer therapies.
BioMed Res Int. 2014:8045102014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsai TF, Lin YC, Chen HE, Chou KY, Lin JF
and Hwang TI: Involvement of the insulin-like growth factor I
receptor and its downstream antiapoptotic signaling pathway is
revealed by dysreg-ulated microRNAs in bladder carcinoma. Urol Sci.
25:58–64. 2014. View Article : Google Scholar
|
|
15
|
Huang HG, Luo X, Wu S and Jian B: MiR-99a
inhibits cell proliferation and tumorigenesis through targeting
mTOR in human anaplastic thyroid cancer. Asian Pac J Cancer Prev.
16:4937–4944. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang Z, Han Y, Cheng K, Zhang G and Wang
X: miR-99a directly targets the mTOR signalling pathway in breast
cancer side population cells. Cell Prolif. 47:587–595. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin JF, Lin YC, Lin YH, Tsai TF, Chou KY,
Chen HE and Hwang TI: Zoledronic acid induces autophagic cell death
in human prostate cancer cells. J Urol. 185:1490–1496. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Varkonyi-Gasic E, Wu R, Wood M, Walton EF
and Hellens RP: Protocol: A highly sensitive RT-PCR method for
detection and quantification of microRNAs. Plant Methods. 3:122007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin CJ, Gong HY, Tseng HC, Wang WL and Wu
JL: miR-122 targets an anti-apoptotic gene, Bcl-w, in human
hepatocellular carcinoma cell lines. Biochem Biophys Res Commun.
375:315–320. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ebert MS, Neilson JR and Sharp PA:
MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian
cells. Nat Methods. 4:721–726. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ebert MS and Sharp PA: MicroRNA sponges:
Progress and possibilities. RNA. 16:2043–2050. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Deng L, Yang SB, Xu FF and Zhang JH: Long
noncoding RNA CCAT1 promotes hepatocellular carcinoma progression
by functioning as let-7 sponge. J Exp Clin Cancer Res. 34:182015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tsai TF, Lin JF, Chou KY, Lin YC, Chen HE
and Hwang TI: miR-99a-5p acts as tumor suppressor via targeting to
mTOR and enhances RAD001-induced apoptosis in human urinary bladder
urothelial carcinoma cells. OncoTargets Ther. 11:239–252. 2018.
View Article : Google Scholar
|
|
25
|
Lin YC, Lin JF, Wen SI, Yang SC, Tsai TF,
Chen HE, Chou KY and Hwang TI: Inhibition of high basal level of
autophagy induces apoptosis in human bladder cancer cells. J Urol.
195:1126–1135. 2016. View Article : Google Scholar
|
|
26
|
Sugiyama T, Taniguchi K, Matsuhashi N,
Tajirika T, Futamura M, Takai T, Akao Y and Yoshida K: MiR-133b
inhibits growth of human gastric cancer cells by silencing pyruvate
kinase muscle-splicer polypyrimidine tract-binding protein 1.
Cancer Sci. 107:1767–1775. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Cheng R and Huang Y: MiR-30a
inhibits BECN1-mediated autophagy in diabetic cataract. Oncotarget.
8:77360–77368. 2017.PubMed/NCBI
|
|
28
|
Fu XT, Shi YH, Zhou J, Peng YF, Liu WR,
Shi GM, Gao Q, Wang XY, Song K, Fan J, et al: MicroRNA-30a
suppresses autophagy-mediated anoikis resistance and metastasis in
hepatocellular carcinoma. Cancer Lett. 412:108–117. 2018.
View Article : Google Scholar
|
|
29
|
Wang S, Wu J, Ren J, Vlantis AC, Li MY,
Liu SY, Ng EK, Chan AB, Luo DC, Liu Z, et al: MicroRNA-125b
Interacts with Foxp3 to Induce Autophagy in Thyroid Cancer. Mol
Ther. 26:2295–2303. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shi G, Shi J, Liu K, Liu N, Wang Y, Fu Z,
Ding J, Jia L and Yuan W: Increased miR-195 aggravates neuropathic
pain by inhibiting autophagy following peripheral nerve injury.
Glia. 61:504–512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rao CV: Benzyl isothiocyanate: Double
trouble for breast cancer cells. Cancer Prev Res (Phila).
6:760–763. 2013. View Article : Google Scholar
|
|
33
|
Tang L and Zhang Y: Dietary
isothiocyanates inhibit the growth of human bladder carcinoma
cells. J Nutr. 134:2004–2010. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Catto JW, Alcaraz A, Bjartell AS, De Vere
White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L,
Schlomm T, et al: MicroRNA in prostate, bladder, and kidney cancer:
A systematic review. Eur Urol. 59:671–681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu SH, Zhang CL, Dong FS and Zhang YM:
miR-99a suppresses the metastasis of human non-small cell lung
cancer cells by targeting AKT1 signaling pathway. J Cell Biochem.
116:268–276. 2015. View Article : Google Scholar
|
|
36
|
Kuo YZ, Tai YH, Lo HI, Chen YL, Cheng HC,
Fang WY, Lin SH, Yang CL, Tsai ST and Wu LW: MiR-99a exerts
anti-metastasis through inhibiting myotubularin-related protein 3
expression in oral cancer. Oral Dis. 20:e65–e75. 2014. View Article : Google Scholar
|
|
37
|
Turcatel G, Rubin N, El-Hashash A and
Warburton D: MIR-99a and MIR-99b modulate TGF-β induced epithelial
to mesenchymal plasticity in normal murine mammary gland cells.
PLoS One. 7:e310322012. View Article : Google Scholar
|
|
38
|
Wang L, Chang L, Li Z, Gao Q, Cai D, Tian
Y, Zeng L and Li M: miR-99a and -99b inhibit cervical cancer cell
proliferation and invasion by targeting mTOR signaling pathway. Med
Oncol. 31:9342014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Peruzzi F, Prisco M, Dews M, Salomoni P,
Grassilli E, Romano G, Calabretta B and Baserga R: Multiple
signaling pathways of the insulin-like growth factor 1 receptor in
protection from apoptosis. Mol Cell Biol. 19:7203–7215. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Plowright EE, Li Z, Bergsagel PL, Chesi M,
Barber DL, Branch DR, Hawley RG and Stewart AK: Ectopic expression
of fibroblast growth factor receptor 3 promotes myeloma cell
proliferation and prevents apoptosis. Blood. 95:992–998.
2000.PubMed/NCBI
|
|
41
|
Castedo M, Ferri KF and Kroemer G:
Mammalian target of rapamycin (mTOR): Pro- and anti-apoptotic. Cell
Death Differ. 9:99–100. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Catto JW, Miah S, Owen HC, Bryant H, Myers
K, Dudziec E, Larré S, Milo M, Rehman I, Rosario DJ, et al:
Distinct microRNA alterations characterize high- and low-grade
bladder cancer. Cancer Res. 69:8472–8481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang H, Li Q, Niu X, Wang G, Zheng S, Fu G
and Wang Z: miR-143 inhibits bladder cancer cell proliferation and
enhances their sensitivity to gemcitabine by repressing IGF-1R
signaling. Oncol Lett. 13:435–440. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Park SJ, Lee TJ and Chang IH: Role of the
mTOR pathway in the progression and recurrence of bladder cancer:
An immunohistochemical tissue microarray study. Korean J Urol.
52:466–473. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hammam O, Aboushousha T, El-Hindawi A,
Khairy H, Khalil H, Kamel A, Akl M, Abdel-Hady A, Magdy M, Badawy
M, et al: Expression of FGFR3 protein and gene amplification in
urinary bladder lesions in relation to schistosomiasis. Open Access
Maced J Med Sci. 5:160–166. 2017.PubMed/NCBI
|
|
46
|
Tang L and Zhang Y: Mitochondria are the
primary target in isothiocyanate-induced apoptosis in human bladder
cancer cells. Mol Cancer Ther. 4:1250–1259. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Singh SV and Singh K: Cancer
chemoprevention with dietary isothiocyanates mature for clinical
translational research. Carcinogenesis. 33:1833–1842. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bader AG: miR-34 - a microRNA replacement
therapy is headed to the clinic. Front Genet. 3:1202012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang Y, Wang Z and Gemeinhart RA:
Progress in microRNA delivery. J Control Release. 172:962–974.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jiang SJ, Ye LY and Meng FH: Comparison of
intravesical bacillus Calmette-Guerin and mitomycin C
administration for non-muscle invasive bladder cancer: A
meta-analysis and systematic review. Oncol Lett. 11:2751–2756.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nogawa M, Yuasa T, Kimura S, Tanaka M,
Kuroda J, Sato K, Yokota A, Segawa H, Toda Y, Kageyama S, et al:
Intravesical administration of small interfering RNA targeting
PLK-1 successfully prevents the growth of bladder cancer. J Clin
Invest. 115:978–985. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Uchino K, Takeshita F, Takahashi RU,
Kosaka N, Fujiwara K, Naruoka H, Sonoke S, Yano J, Sasaki H, Nozawa
S, et al: Therapeutic effects of microRNA-582-5p and -3p on the
inhibition of bladder cancer progression. Mol Ther. 21:610–619.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Inamoto T, Taniguchi K, Takahara K,
Iwatsuki A, Takai T, Komura K, Yoshikawa Y, Uchimoto T, Saito K,
Tanda N, et al: Intravesical administration of exogenous
microRNA-145 as a therapy for mouse orthotopic human bladder cancer
xenograft. Oncotarget. 6:21628–21635. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lamy E, Scholtes C, Herz C and
Mersch-Sundermann V: Pharmacokinetics and pharmacodynamics of
isothiocyanates. Drug Metab Rev. 43:387–407. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hadaschik BA, Black PC, Sea JC, Metwalli
AR, Fazli L, Dinney CP, Gleave ME and So AI: A validated mouse
model for orthotopic bladder cancer using transurethral tumour
inoculation and bioluminescence imaging. BJU Int. 100:1377–1384.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kota J, Chivukula RR, O’Donnell KA,
Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P,
Torbenson M, Clark KR, et al: Therapeutic microRNA delivery
suppresses tumorigenesis in a murine liver cancer model. Cell.
137:1005–1017. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Toffanin S, Villanueva A and Llovet JM:
miRNA delivery: Emerging therapy for hepatocellular carcinoma.
Gastroenterology. 138:1202–1204. 2010. View Article : Google Scholar : PubMed/NCBI
|
